Aspen Alert

HaLCon provides the simplest, fastest, protein concentration measurements – straight from a bioreactor. HaLCon provides real-time antibody concentrations, with all the accuracy, but none of the complexity of HPLC-protein A analysis. HaLCon is now completely automated, introducing the Nest Autosampler! With HaLCon+Nest you can analyze up to 192-samples in one run completely hands-free, analysis time is 5 minutes/sample, and with the simple touchscreen interface it takes less than 15 minutes to train new users. https://lnkd.in/ef-WV6uk #bioprocessing #innovation #monoclonalantibodies #mabs #bioproduction #protein #upstream #downstreamprocessing #cdmo #bioreactor #efficiency #biobusiness #biotherapeutics #hplc #automation #autosampler

Novartis Begins Construction of Two New Radioligand Therapy Facilities in U.S. Novartis has announced the construction of two new radioligand therapy manufacturing facilities in the U.S. that will extend its manufacturing and supply chain capabilities. According to a news release, Novartis broke ground on a new facility at its Indianapolis site that will produce radioisotopes critical for the manufacturing of RLTs. Meanwhile, in Carlsbad, California, Novartis is establishing its third RLT manufacturing site in the U.S. to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Both facilities will be built with room for further expansion to enable the potential production of different isotopes, ligands and RLTs. Once completed and approved, these new facilities will further strengthen the Novartis RLT manufacturing and supply network. https://lnkd.in/gAjxbUKW #aspenalert #biotech #bioprocess

ArsenalBio Snags Mega $325M Series C Round with Backing from Nvidia, Regeneron Cell therapy biotech ArsenalBio has raised a massive $325 million Series C funding round, wrapping up ARCH Venture Partners, Regeneron Ventures and Nvidia’s venture capital arm NVentures as new investors, among others. The cash will be used to fuel ArsenalBio’s solid tumor candidates that use a proprietary T cell technology. The company will also seek to boost its tools and processes for finding new cell therapies. The biotech’s pipeline includes candidates for ovarian, kidney and prostate cancers. Candidates for other solid tumors are being developing in a partnership with BMS. “Our initial clinical trials and preclinical studies have shown the promise of our T cell engineering approach and have given us the confidence to broaden the application of our technology to address additional cancer types,” ArsenalBio CEO Ken Drazan said in a statement. https://lnkd.in/g2iq9f-9 #aspenalert #biotech #bioprocess

The ISPE Boston Product Show is just a month away! Join flow experts from Brooks Instrument on October 2, Booth W136 at Gillette-Stadium. This is a fantastic opportunity for us to connect with industry leaders like you, showcase our latest innovations, and explore how we can support your goals. Here's What You Can Expect: - Innovative Solutions: Discover our newest technologies for all phases of biopharmaceutical drug production, designed to improve process gas control and maximize flexibility with capability for in-situ calibrations and verification. - Interactive Demos: Experience hands-on demonstrations of our advanced alarms and diagnostics to get a firsthand look at how our mass flow controllers can alert you to a process issue then give guidance on what to do. - Expert Insights: Engage in insightful discussions with our experts and gain valuable knowledge about our system design and automation recommendations. Register for the show: https://lnkd.in/dsN2Qc7 #BrooksInstrument #aspenalert #ispe

CFD Predictive Simulations of Bioreactor Mixing Dynamics Coupled with Photo-Bioreaction Kinetics in Transitional Flow Regime Fluctuating hydrodynamics in mechanically mixed bioreactors present numerical challenges for coupling (bio)reaction kinetics, critical for optimization and scale-up/down in chemical and bioprocess industries. This study achieved hydrodynamic convergence by time-averaging instantaneous RANS solutions of the transitional SST model and, for the first time, solved photo-bioreaction transport models based on these converged fields, overcoming previous two-step coupling challenges. Applied to a 0.7 L Schott bottle photobioreactor mixed by a magnetic stirrer (100-500 rpm), rigorous validations with literature photo-bioreaction data and experimental tracer datasets, accurately predicted swirly vortex fields at 500 rpm, within 7% error margin for simulated tracer diffusion. Biomass growth profiles matched previous studies, affirming the approach’s reliability and computational efficiency. https://lnkd.in/gSZT8AHA #aspenalert #biotech #bioprocess

Vaxcyte's 'Stunning' 31-Valent Pneumococcal Vaccine Win Against Pfizer's Prevnar 20 has Analysts Thinking Big Vaxcyte unveiled what analysts called “stunning” phase 1/2 data for its 31-valent pneumococcal vaccine candidate that, if replicated in a large pivotal study, could pose a serious threat to Pfizer’s stalwart Prevnar 20. The phase 1/2 Prevnar 20 head-to-head data that Vaxcyte revealed for its VAX-31 in adults ages 50 and older are “exceptional” and suggest “a pneumococcal conjugate vaccine category killer profile,” Leerink Partners analysts said in a note. One key point from the readout that excited analysts is the fact that VAX-31, at both the middle and high doses, showed antibody immune responses—as measured by opsonophagocytic activity assay—that either matched or exceeded those of Prevnar 20 for the 20 serotypes shared between the two shots. https://lnkd.in/g53wnAz5 #aspenalert #biotech #bioprocess

An Artificial Intelligence Model for Solving Chromatographic Gradient Elution Curves Artificial intelligence (AI) has been successfully applied in many fields of society, but it has not yet been explored in the modeling of chromatographic separation systems. Therefore, this paper aims to introduce recurrent neural networks and combine tray theory in liquid chromatography to establish an artificial intelligence model for describing chromatographic separation processes. The model format is simple and easy to solve, with the concentration of components in the mobile phase at the inflow and outflow of the tray as the input and output layers, respectively. By solving the model, chromatographic elution curves can be obtained. The model was applied to predict the gradient elution experiment of 2-naphthol, and the results showed that the gradient elution curve calculated by the model matched well with the experimental curve. https://lnkd.in/gUjycufp #aspenalert #biotech #bioprocess

Dialysis Rolled Scaffold Bioreactor Allows Extended Production of Monoclonal Antibody with Reduced Media Use In this study, a dialysis rolled scaffold bioreactor was presented for long-term production of monoclonal antibodies with reduced media consumption. Media dialysis can selectively remove cellular bio-wastes without losing cells or produced recombinant proteins. The dialysis process was streamlined to significantly improve its efficiency. Then, extended culture of recombinant CHO cells for 41 days was successfully demonstrated with consistent production rate and minimal media consumption. The unique configuration of the developed bioreactor allows efficient dialysis for media management, as well as rapid media exchange to harvest produced recombinant proteins before they degrade. Taken together, it was envisioned that the developed bioreactor will enable cost-effective and long-term large-scale culture of various cells for biopharmaceutical production. https://lnkd.in/gVXSKqsj #aspenalert #biotech #bioprocess

New Data Reveal How Bayer's Asundexian Failed to Prevent Strokes, Imperiling $5.5B Blockbuster Hopes Bayer suspended the phase 3 trial for its factor XIa inhibitor asundexian late last year after the drug showed “inferior efficacy” at preventing strokes in patients with atrial fibrillation compared to Bristol Myers Squibb and Pfizer’s Eliquis. The full picture of what that “inferior efficacy” looks like has now come into focus: Patients receiving asundexian actually suffered strokes or systemic embolisms at a higher rate than those receiving Eliquis. In a 14,810-patient study, dubbed OCEANIC-AF, 98 patients receiving Bayer’s drug suffered strokes or systemic embolisms, compared to 26 patients receiving Eliquis, at the time the trial was called off prematurely because of the concerning trend, according to trial results published Sept. 1 in The New England Journal of Medicine. Preventing stroke was the trial’s primary efficacy endpoint. https://lnkd.in/gqTy3YiU #aspenalert #biotech #bioprocess

Scaling Up HEK Cell Culture Process from 250mL to 5L Bioreactor with Consistent Performance in Culture Biosciences Cloud-Connected Bioreactors Human embryonic kidney cells are widely used in gene therapy and other therapeutic expression processes. They possess several key attributes that make them good hosts for genetic modification and gene therapy expression. Here we describe the growth of suspension adapted HEK293 cells in 250mL and 5L bioreactors. We monitored viable cell density and viability along with metabolites ammonium, lactate, and glutamine. All measurements reached the same end points, with viable cell density, viability, lactate and glutamine following similar trends between scales. https://lnkd.in/gSWqrv8D #aspenalert #biotech #bioprocess